Filter per year
December 1, 2023
Press Release: Sanofi’s Consumer Healthcare unit launches the Shared Care Collective, an advisory group working to advance sustainability
November 27, 2023
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
November 9, 2023
Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)
October 27, 2023
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
October 27, 2023
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
October 22, 2023
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
October 20, 2023
Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
October 19, 2023
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
October 18, 2023
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
October 13, 2023
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
October 6, 2023
Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease
October 4, 2023
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
October 3, 2023
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
October 2, 2023
Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
September 26, 2023
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
September 25, 2023
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
September 22, 2023
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
September 19, 2023
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
September 14, 2023
Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD